Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad)
NASDAQ:SKYE

Skye Bioscience 11/13/2023 Earnings Report

Skye Bioscience logo
$2.21 +0.24 (+12.18%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 -0.04 (-1.58%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Skye Bioscience EPS Results

Actual EPS
-$3.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skye Bioscience Announcement Details

Quarter
Date
11/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Skye Bioscience Earnings Headlines

Arecor shares climb 18% on collaboration with Skye Bioscience
May 19 at 12:53 PM | lse.co.uk
Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
May 19 at 7:51 AM | finanznachrichten.de
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
May 21, 2025 | Paradigm Press (Ad)
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
May 19 at 5:00 AM | globenewswire.com
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2025 | globenewswire.com
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
May 13, 2025 | globenewswire.com
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE), a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

View Skye Bioscience Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles